secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021914
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Dyadic International Reports Q3 2025 Financial Results and Strategic Progress
-----------------------------------------------------------------------------

- Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.
- Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.
- Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.
- Secured ERS Genomics CRISPR license to optimize protein production.
- Received $1.5 million in milestone payments from Proliant for animal-free serum albumin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/0001493152-25-021914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer